hepatology Archives -

NGM craters after dropping mid-stage NASH candidate aldafermin

https://pharmaphorum.com/news/ngm-craters-after-dropping-mid-stage-nash-candidate-aldafermin/

Novo Nordisk’s gene silencing alliance with Dicerna bears first fruit

https://pharmaphorum.com/news/novo-nordisks-gene-silencing-alliance-with-dicerna-bears-first-fruit/

Gilead and Novo plot next steps after trial data from NASH combo

https://pharmaphorum.com/news/gilead-and-novo-plot-next-steps-after-encouraging-data-from-nash-combo/

Genfit abandons late-stage trial of NASH drug elafibranor

https://pharmaphorum.com/news/genfit-abandons-late-stage-trial-of-nash-drug-elafibranor/

Another NASH setback as CymaBay drops seladelpar

https://pharmaphorum.com/news/another-nash-setback-as-cymabay-drops-seladelpar/

Novartis takes $80M punt on early-stage NASH drug from Pliant

https://pharmaphorum.com/news/novartis-takes-80m-punt-on-early-stage-nash-drug-from-pliant/

Alnylam hopes for 2018 filing for RNAi liver disease drug

https://pharmaphorum.com/news/alnylam-hopes-2018-filing-rnai-liver-disease-drug/

Novo Nordisk board member quits over NASH conflict of interest

https://pharmaphorum.com/news/novo-nordisk-board-member-quits-nash/

Can Gilead find another Pharmasset in 2017?

https://pharmaphorum.com/news/can-gilead-find-another-pharmasset-2017/

Search